MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
9.35
+0.26
+2.86%
Opening 14:35 12/05 EST
OPEN
9.16
PREV CLOSE
9.09
HIGH
9.43
LOW
9.11
VOLUME
549.50K
TURNOVER
--
52 WEEK HIGH
10.38
52 WEEK LOW
1.450
MARKET CAP
682.43M
P/E (TTM)
-3.4612
1D
5D
1M
3M
1Y
5Y
1D
Lexeo Therapeutics Hosts Virtual Clinician Event on PKP2-Associated Arrhythmogenic Cardiomyopathy
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 3d ago
Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 4d ago
Lexeo Therapeutics Price Target Announced at $19.00/Share by Cantor Fitzgerald
Dow Jones · 4d ago
Cantor Fitzgerald Initiates Coverage On Lexeo Therapeutics with Overweight Rating, Announces Price Target of $19
Benzinga · 4d ago
Weekly Report: what happened at LXEO last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at LXEO last week (1117-1121)?
Weekly Report · 11/24 10:23
Lexeo Therapeutics CEO Makes Significant Stock Sale!
TipRanks · 11/21 02:04
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.